<p>中国泛华资产管理有限公司在第四季度收购了 Abivax SA 赞助的 ADR（NASDAQ:ABVX - 免费报告）的新股份，根据该公司在最近向美国证券交易委员会提交的 13F 文件。该机构投资者收购了 11,619 股公司股票，价值约为 1,567,000 美元。</p>
<p>其他一些对冲基金和机构投资者最近也对该公司的持仓进行了调整。杰富瑞金融集团在第三季度购买了 Abivax 的新头寸，价值约为 38,827,000 美元。联邦赫尔墨斯公司在第三季度购买了 Abivax 股票的新股份，价值约为 8,448,000 美元。Persistent Asset Partners Ltd 在第三季度购买了 Abivax 股票的新股份，价值约为 815,000 美元。Atika Capital Management LLC 在第三季度收购了 Abivax 股票的新头寸，价值约为 5,858,000 美元。最后，Tudor Investment Corp ET AL 在第三季度收购了 Abivax 股票的新头寸，价值约为 2,792,000 美元。47.91% 的股票由机构投资者持有。</p>
<h2>Abivax 价格表现</h2>
<p>NASDAQ ABVX 周五开盘价为 114.56 美元。该股票的 50 日简单移动平均线为 118.27 美元，200 日简单移动平均线为 115.69 美元。Abivax SA 赞助的 ADR 一年低点为 5.59 美元，一年高点为 148.83 美元。该公司的市值为 90.8 亿美元，市盈率为 -21.33，贝塔值为 1.68。</p>
<p>Abivax（NASDAQ:ABVX - 获取免费报告）最近于 2 月 14 日星期六发布了季度财报。该公司报告每股收益（EPS）为 -1.20 美元。该季度的营业收入为 52 万美元。整体来看，股票分析师预计 Abivax SA 赞助的 ADR 在当前年度将发布 -3.84 的每股收益。</p>
<h2>分析师评级上调与下调</h2>
<p>ABVX 最近成为几份分析师报告的主题。Weiss Ratings 在周一的研究报告中重申了对 Abivax 股票的 &#34;卖出（d-）&#34; 评级。BTIG Research 在 2 月 25 日星期三的报告中重新发布了 &#34;买入&#34; 评级，并设定了 150.00 美元的价格目标。花旗集团在 1 月 8 日星期四的研究报告中重申了对 Abivax 股票的 &#34;市场表现优于大盘&#34; 评级。巴克莱在 3 月 24 日星期二的报告中将 Abivax 股票的目标价格从 142.00 美元上调至 148.00 美元，并给予该股票 &#34;增持&#34; 评级。最后，Wedbush 在 2 月 24 日星期二的研究报告中开始覆盖 Abivax 股票。他们设定了 &#34;表现优于大盘&#34; 的评级和 110.00 美元的目标价格。一位股票研究分析师对该股票给予了强烈买入评级，十三位给予了买入评级，一位给予了卖出评级。根据 MarketBeat 的数据，Abivax 的平均评级为 &#34;适度买入&#34;，共识价格目标为 137.15 美元。</p>
<p><strong>查看我们对 Abivax 的最新分析</strong></p>
<h2>关于 Abivax</h2>
<p>（免费报告）</p>
<p>Abivax 成立于 2013 年，总部位于法国巴黎，是一家临床阶段的生物制药公司，专注于发现和开发用于慢性炎症性疾病和病毒感染的新疗法。该公司的技术平台针对宿主 RNA 生物发生，以调节关键免疫通路，提供旨在疾病修饰和改善安全性特征的差异化方法。</p>
<p>Abivax 的主要临床资产 obefazimod（ABX464）正在评估用于溃疡性结肠炎和其他炎症性疾病。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，优于 Abivax</li>
</ul>
<p><strong>想看看其他对冲基金持有的 ABVX 吗？</strong> 访问 HoldingsChannel.com 获取 Abivax SA 赞助的 ADR（NASDAQ:ABVX - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJWWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJWWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Abivax 吗？</h2>
<p>在考虑 Abivax 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Abivax 并不在名单上。</p>
<p>虽然 Abivax 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ABVX

动态生物技术与基因组 ETF - Invesco

纳斯达克生物科技指数 ETF - iShares Nasdaq

生物科技 ETF - VanEck Vectors

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 3 倍做多 - Direxion

<p>中国泛华资产管理有限公司在其最近的 13F 文件中报告，已收购 11,619 股 Abivax SA 赞助的 ADR（NASDAQ:ABVX），价值约为 157 万美元。其他机构投资者也增加了对 Abivax 的持股。该股票的市值为 90.8 亿美元，市盈率为-21.33。分析师对 Abivax 的评级褒贬不一，普遍评级为 “适度买入”，目标价格为 137.15 美元。Abivax 专注于开发慢性炎症疾病和病毒感染的治疗方案</p>

<p>China Universal Asset Management Co. Ltd. acquired a new stake in Abivax SA Sponsored ADR (NASDAQ:ABVX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 11,619 shares of the company's stock, valued at approximately $1,567,000.</p>
<div class="lb-trans"><p>中国泛华资产管理有限公司在第四季度收购了 Abivax SA 赞助的 ADR（NASDAQ:ABVX - 免费报告）的新股份，根据该公司在最近向美国证券交易委员会提交的 13F 文件。该机构投资者收购了 11,619 股公司股票，价值约为 1,567,000 美元。</p>
</div><p>A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Jefferies Financial Group Inc. bought a new position in Abivax during the third quarter worth about $38,827,000. Federated Hermes Inc. bought a new stake in shares of Abivax in the 3rd quarter valued at approximately $8,448,000. Persistent Asset Partners Ltd bought a new stake in shares of Abivax in the 3rd quarter valued at approximately $815,000. Atika Capital Management LLC acquired a new position in shares of Abivax in the 3rd quarter worth approximately $5,858,000. Finally, Tudor Investment Corp ET AL acquired a new position in shares of Abivax in the 3rd quarter worth approximately $2,792,000. 47.91% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他一些对冲基金和机构投资者最近也对该公司的持仓进行了调整。杰富瑞金融集团在第三季度购买了 Abivax 的新头寸，价值约为 38,827,000 美元。联邦赫尔墨斯公司在第三季度购买了 Abivax 股票的新股份，价值约为 8,448,000 美元。Persistent Asset Partners Ltd 在第三季度购买了 Abivax 股票的新股份，价值约为 815,000 美元。Atika Capital Management LLC 在第三季度收购了 Abivax 股票的新头寸，价值约为 5,858,000 美元。最后，Tudor Investment Corp ET AL 在第三季度收购了 Abivax 股票的新头寸，价值约为 2,792,000 美元。47.91% 的股票由机构投资者持有。</p>
</div><h2>Abivax Price Performance</h2>
<div class="lb-trans"><h2>Abivax 价格表现</h2>
</div><p>NASDAQ ABVX opened at $114.56 on Friday. The stock's 50 day simple moving average is $118.27 and its 200 day simple moving average is $115.69. Abivax SA Sponsored ADR has a one year low of $5.59 and a one year high of $148.83. The firm has a market cap of $9.08 billion, a PE ratio of -21.33 and a beta of 1.68.</p>
<div class="lb-trans"><p>NASDAQ ABVX 周五开盘价为 114.56 美元。该股票的 50 日简单移动平均线为 118.27 美元，200 日简单移动平均线为 115.69 美元。Abivax SA 赞助的 ADR 一年低点为 5.59 美元，一年高点为 148.83 美元。该公司的市值为 90.8 亿美元，市盈率为 -21.33，贝塔值为 1.68。</p>
</div><p>Abivax (NASDAQ:ABVX - Get Free Report) last issued its quarterly earnings data on Saturday, February 14th. The company reported ($1.20) earnings per share (EPS) for the quarter. The business had revenue of $0.52 million during the quarter. As a group, equities analysts expect that Abivax SA Sponsored ADR will post -3.84 earnings per share for the current year.</p>
<div class="lb-trans"><p>Abivax（NASDAQ:ABVX - 获取免费报告）最近于 2 月 14 日星期六发布了季度财报。该公司报告每股收益（EPS）为 -1.20 美元。该季度的营业收入为 52 万美元。整体来看，股票分析师预计 Abivax SA 赞助的 ADR 在当前年度将发布 -3.84 的每股收益。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><p>ABVX has been the topic of several recent analyst reports. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Abivax in a research note on Monday. BTIG Research reissued a &#34;buy&#34; rating and set a $150.00 price objective on shares of Abivax in a report on Wednesday, February 25th. Citigroup restated a &#34;market outperform&#34; rating on shares of Abivax in a research note on Thursday, January 8th. Barclays upped their target price on shares of Abivax from $142.00 to $148.00 and gave the stock an &#34;overweight&#34; rating in a report on Tuesday, March 24th. Finally, Wedbush initiated coverage on shares of Abivax in a research report on Tuesday, February 24th. They set an &#34;outperform&#34; rating and a $110.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Abivax has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $137.15.</p>
<div class="lb-trans"><p>ABVX 最近成为几份分析师报告的主题。Weiss Ratings 在周一的研究报告中重申了对 Abivax 股票的 &#34;卖出（d-）&#34; 评级。BTIG Research 在 2 月 25 日星期三的报告中重新发布了 &#34;买入&#34; 评级，并设定了 150.00 美元的价格目标。花旗集团在 1 月 8 日星期四的研究报告中重申了对 Abivax 股票的 &#34;市场表现优于大盘&#34; 评级。巴克莱在 3 月 24 日星期二的报告中将 Abivax 股票的目标价格从 142.00 美元上调至 148.00 美元，并给予该股票 &#34;增持&#34; 评级。最后，Wedbush 在 2 月 24 日星期二的研究报告中开始覆盖 Abivax 股票。他们设定了 &#34;表现优于大盘&#34; 的评级和 110.00 美元的目标价格。一位股票研究分析师对该股票给予了强烈买入评级，十三位给予了买入评级，一位给予了卖出评级。根据 MarketBeat 的数据，Abivax 的平均评级为 &#34;适度买入&#34;，共识价格目标为 137.15 美元。</p>
</div><p><strong>View Our Latest Analysis on Abivax</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Abivax 的最新分析</strong></p>
</div><h2>About Abivax</h2>
<div class="lb-trans"><h2>关于 Abivax</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.</p>
<div class="lb-trans"><p>Abivax 成立于 2013 年，总部位于法国巴黎，是一家临床阶段的生物制药公司，专注于发现和开发用于慢性炎症性疾病和病毒感染的新疗法。该公司的技术平台针对宿主 RNA 生物发生，以调节关键免疫通路，提供旨在疾病修饰和改善安全性特征的差异化方法。</p>
</div><p>Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.</p>
<div class="lb-trans"><p>Abivax 的主要临床资产 obefazimod（ABX464）正在评估用于溃疡性结肠炎和其他炎症性疾病。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Abivax</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，优于 Abivax</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ABVX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abivax SA Sponsored ADR (NASDAQ:ABVX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 ABVX 吗？</strong> 访问 HoldingsChannel.com 获取 Abivax SA 赞助的 ADR（NASDAQ:ABVX - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJWWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=ABVX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Abivax Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Abivax 吗？</h2>
</div><p>Before you consider Abivax, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Abivax 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abivax wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Abivax 并不在名单上。</p>
</div><p>While Abivax currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Abivax 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

China Universal Asset Management Co. Ltd. Purchases Shares of 11,619 Abivax SA Sponsored ADR $ABVX

Market Beat

Abivax SA

Jefferies Financial

Federated Hermes

花旗

巴克莱银行

CITIGROUP INC 6.250 NON CUM SER II PFD WI

中国广发资产管理有限公司购买了 11,619 股 Abivax SA 赞助的美国存托凭证$ABVX